6 results about "Dopamine transporter" patented technology

A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.

The application discloses a dopamine transporter dynamics mechanism-based mental stimulant addiction risk prediction method, and belongs to the field of computer-aided drug design and biological computing simulation. The method comprises the following steps: firstly, preparing a conformation and constructing a drug-target-membrane environment; then, performing classical molecular dynamics (cMD) simulation and binding affinity evaluation; then, extracting a dissociation energy barrier by using stretching molecular dynamics (SMD); then, extracting a binding path based on a ligand binding-parallel cascade molecular dynamics (LB-PaCS-MD) and a Markov state model; and finally, comprehensively evaluating addiction and screening drugs. By using the method, a dynamic dissociation / binding path can be accurately mapped on a full-atom level, and a residence time parameter can be calculated, so as to guide accurate development of low-addiction mental drugs.

In the present invention, a deuterium-substituted FP-CIT linear precursor is developed in order to increase the linear stability of a precursor. When the deuterium-substituted FP-CIT linear precursor according to the present invention is dissolved in an organic solvent and stored, linearity is maintained well even at room temperature, and the same effect as a conventional radiopharmaceutical product [18F]FP-CIT is exhibited. In addition, D6-[18F]FP-CIT can be prepared simply and in a high yield, and thus can be effectively used as a starting material for the synthesis of D6-[18F]FP-CIT. Furthermore, a novel radiopharmaceutical product D6-[18F]FP-CIT enables visualization of dopamine transporter (DAT) distribution to be performed through improved image contrast, and has particularly high accuracy in diagnosing Parkinson's disease and related degenerative brain diseases, and thus can be effectively used.

The invention discloses application of a miR-6809-5p inhibitor, and belongs to the technical field of biological medicine.The inventor finds that expression of miR-6809-5p in plasma of a PD patient is abnormally increased in the research of PD pathogenesis, and further cell experiments find that the expression of miR-6809-5p is abnormally increased in the plasma of the PD patient. By inhibiting the expression of the miR-6809-5p, the adverse effects of MPP + on cell viability, apoptosis, ROS, p-alpha-syn and TH protein can be effectively improved, and the miR-6809-5p has a remarkable treatment effect on PD. MPP + is an active metabolite of neurotoxin MPTP, can be selectively absorbed by dopaminergic neurons through dopamine transporter (DAT) protein to trigger degeneration death of the dopaminergic neurons, and is widely applied to construction of PD cell models to research pathogenesis of PD and drug evaluation. The miR-6809-5p inhibitor disclosed by the invention is used for preparing a medicine for treating the Parkinson's disease, and the nucleotide sequence of the miR-6809-5p inhibitor is as follows: UGAUCCUUUCUUUCCUUGCCA.

To provide anti-DAT antibodies and compositions thereof for slowing the progression of Parkinson's disease.SOLUTION: Anti-DAT antibodies are formed by transcription and translation of gene fragments containing specific sequences. The anti-DAT antibody provided by the present invention is used for labeling a dopamine transporter. The anti-DAT antibody provided by the present invention is capable of forming a composition that crosses the blood-brain barrier, is capable of specifically binding to dopaminergic neurons, and is capable of specifically binding to cells in the striatum The use of reducing the deposition of α - synuclein protein in the brain region is achieved, and the excellent effect of delaying the progress of Parkinson's disease is exerted.SELECTED DRAWING: Figure 1

A targeting vector includes an extracellular vesicle in which a dopamine transporter antibody is bound to a transmembrane protein, the extracellular vesicle is secreted by a cell genetically transfected with a vector gene, and at least a portion of the vector gene includes SEQ ID No: 1. The targeting carrier provided by the invention can be used for loading a medicine to pass through a blood brain barrier, can achieve specific binding aiming at dopamine nerve cells, and achieves excellent effects of regulating secretion of marker protein of Parkinson's disease and delaying the course of Parkinson's disease.